Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 MCG for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Value in Health- United Kingdom
doi 10.1016/j.jval.2013.08.1834
Full Text
Abstract
Available in
Date
November 1, 2013
Authors
Publisher
Elsevier BV